Needham & Company Reiterates a 'Buy' on NxStage Medical (NXTM); The Devil is in the Details; Home Hemo Solid ex-OUS

Needham & Company reiterates a 'Buy' on NxStage Medical (NASDAQ: NXTM) price target raised from $28.50 to $31.00.

Needham analyst, William J. Plovanic, said, "We reiterate our rating post mixed Q3/11 results. Revenues were driven by growth in the US home hemo business, and strength in the hospital and In-Center businesses. Weakness in OUS home hemo sales drew investor concern, but is likely transitory. Gross margins and operating profits were negatively skewed by manufacturing transition of a product line. We believe NxStage’s System One is positioned to capture a meaningful share of the dialysis market over time."

For more ratings news on NxStage Medical click here and for the rating history of NxStage Medical click here.

Shares of NxStage Medical closed at $19.78 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Keefe, Bruyette & Woods Upgrades Nayax (NYAX) to Outperform
• ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)